Article Figures & Data
Figures
- Figure 1.
Mean insulin dose and mean HbA1c value, by visit: N=379.
HbA1C—glycated hemoglobin, U—unit, V—visit.
*Insulin initiation.
- Figure 2.
Patients’ HbA1c values, by visit: N=379
HbA1c—glycated hemoglobin, V—visit.
*Insulin initiation.
Tables
CHARACTERISTIC N MEAN (SD) Age, y 379 63.5 (12.8) Age at T2DM diagnosis, y 370* 50.7 (12.6) Weight at time of insulin initiation, kg 361* 87.3 (22.6) Time from diagnosis to insulin initiation, y 365* 9.2 (6.5) HbA1c level before insulin initiation, % 369* 9.51 (1.89) -
HbA1c—glycated hemoglobin, SD—standard deviation, T2DM—type 2 diabetes mellitus.
-
↵* Not all patients are included owing to missing data.
-
PARAMETER VISIT 1 VISIT 2 VISIT 3 DIFFERENCE BETWEEN VISIT 1 AND VISIT 3* Median interval, y Initiation 1.2 2.7 3.9 Mean HbA1c, %† (mean change since last visit†) 9.5 8.1 (−1.50) 7.9 (−0.13) −1.63 Mean weight, kg† (mean change since last visit†) 87.3 90 (+2.08) 91.4 (+1.25) +3.45 Mean daily insulin dose, U† (mean change since last visit†) 24 48 (+24) 65.4 (+16.4) +41.0 Mean insulin dose per kilogram, U† (mean change since last visit†) 0.28 0.54 (+0.26) 0.72 (+0.18) +0.43 No. of injections per day (% of patients) 1 (48.5) 1 (20.9) 1 (13.0) 1 (−35.5) 2 (39.5) 2 (54.4) 2 (45.4) 2 (+5.9) 3+ (12.1) 3+ (24.8) 3+ (41.6) 3+ (+29.5) CLASS PROPORTION OF PATIENTS VISIT 1 VISIT 2 VISIT 3 Metformin 63.5 56.7 52.8 Thiazolidinediones 10.5 10.0 7.9 Sulfonylureas 26.3 17.1 11.3 Meglitinides 5.0 2.9 2.6 α-Glucosidase inhibitors 1.6 0.5 0.8 Orlistat 0.8 1.0 0.8 Combination formulations 1.3 0.3 1.0
In this issue
Jump to section
Related Articles
Cited By...
- Evaluation of a unique and innovative diabetes care model in primary care in Ontario, Canada: protocol for a multiple-methods study with a convergent parallel design
- Effect of Diabetes-Trained Nurse Practitioners on Glycemic Outcomes: Their Suggested Use in Busy Primary Care Practices
- Therapeutic Inertia in People With Type 2 Diabetes in Primary Care: A Challenge That Just Wont Go Away
- Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
- Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications
- When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump
- Insulin Therapy: A Personal Approach
- Why do some people with type 2 diabetes who are using insulin have poor glycaemic control? A qualitative study
- Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: A Randomized Noninferiority Trial
- Results of a Mixed-Methods Evaluation of Partnerships for Health: A Quality Improvement Initiative for Diabetes Care
- Impact of Baseline Insulin Regimen on Glycemic Response to a Group Medical Clinic Intervention